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Angiogenesis mediated by vascular endothelial growth factor (VEGF) is a
hallmark of glioblastoma. Moreover, VEGF may exert tumor-intrinsic sur-
vival properties mediated both by VEGF receptors 1 and 2. Although
various VEGF inhibitors have shown limited clinical activity in glioblastoma,
notably determined by responses on neuroimaging and prolongation of
progression-free survival (PFS), no VEGF antagonist has so far been demon-
strated to unequivocally improve overall survival in any clinical setting in glio-
blastoma. Based on response rates and improved PFS, although not overall
survival (OS), the 149 kDa anti-VEGF-A IgG antibody bevacizumab
(Avastinw) is approved in the US and Japan for recurrent glioblastoma and
in Japan for newly diagnosed glioblastoma. However, it is not approved in
the EU. Here we characterize DLX1008, a 26 kDa anti-VEGF-A single
chain antibody fragment which binds with 22 pM and 27 pM affinity to
mouse and human VEGF-A, respectively. In vitro, in a tube formation assay
with human cerebral microvascular endothelial cells (HCMEC), it was dem-
onstrated that DLX1008 is at least as active as Avastinw. In addition,
DLX1008 showed superiority to Avastinw in the inhibition of VEGF-A
binding toVEGF-R1 inELISAbya factorof around10. In vivo,DLX1008 sig-
nificantly improved survival in amouse orthotopicU87 xenograftmodel com-
pared to vehicle control (p ¼ 0.00026) and significantly inhibited tumor
growth in a mouse subcutaneous U87 xenograft model compared to vehicle
control (p ¼ 0.0021). In summary, thesedatawarrant further clinical develop-
ment of DLX1008 in a biomarker-driven approach to glioblastoma.
DLX1008 may provide improved clinical benefit in glioblastoma, especially
in overall survival, due to higher affinity and smaller size leading to improved
tumor penetration.
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